Genfit : Un 10 juin crucial pour le groupe
>89 M€ à percevoir d’Ipsen en 2024, assurant une visibilité financière à fin 2025 - Genfit publiait hier soir ses résultats annuels 2023 qui se révèlent supérieurs à nos attentes. Les produits d’exploitations ressortent à 38 M€ en incluant notamment 13 M€ facturé à Ipsen, 9 M€ de revenus venant de la reconnaissance partielle des 40 M€ versés en 2021 et 6.5 M€ de services pour ses derniers. Les subventions et crédits d’impôts recherche permettent de compléter les reven...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.